Doxorubicin Hydrochloride Liposome and Bortezomib in Treating Patients With Refractory Hematologic Cancer or Malignant Solid Tumor or Metastatic Breast Cancer

DISEASE CHARACTERISTICS: Phase I (closed to accrual as of 10/15/2007) * Histologically or cytologically confirmed solid tumor or hematologic malignancy, including, but not limited to, any of the following: * Breast cancer * Ovarian cancer * Myeloid or lymphoid leukemia * Hodgkin or non-Hodgkin lymphoma * Multiple myeloma * Measurable or evaluable disease * Must meet 1 of the following criteria: * Refractory to at least one prior conventional treatment regimen * Not a candidate for conventional therapy * No conventional therapy exists * No clinically or radiographically significant pleural or pericardial effusion * Patients with ascites may be eligible at the discretion of the investigator * Previously treated central nervous system disease allowed provided it has been stable for \> 3 months and it is not the only site of measurable disease * Not eligible for a higher priority protocol Phase II * Diagnosis of breast cancer * Metastatic disease * Measurable disease by RECIST criteria * No symptomatic brain metastases * Patients with treated brain metastases that have been stable for \> 3 months and does not require chronic steroids are eligible * Hormone receptor status not specified PATIENT CHARACTERISTICS: Phase I (closed to accrual as of 10/15/2007) * Karnofsky performance status 60-100% * Life expectancy ≥ 2 months * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception * WBC ≥ 2,000/mm³ * ANC ≥ 1,500/mm³ (≥ 1,000/mm³ for patients with marrow infiltration) * Platelet count ≥ 100,000/mm³ (≥ 50,000/mm³ for patients with marrow infiltration) * Hemoglobin ≥ 8 g/dL * Creatinine ≤ 2.5 mg/dL OR creatinine clearance ≥ 30 mL/min * AST and ALT \< 2.5 times upper limit of normal (ULN) * Total bilirubin \< 1.2 times ULN * Prothrombin time (PT) and activated partial thromboplastin time (aPTT) \< 1.5 times ULN * Patients receiving warfarin or heparin therapy for a history of thrombosis, embolism, or other indication must have PT and/or aPTT within the accepted therapeutic ranges for those indications * Patients with a history of reactions to other liposomal drug formulations that are not due to the liposome itself may be eligible at the discretion of the investigator * No known HIV seropositivity * No known active hepatitis A, B, or C viral infection * No New York Heart Association class III or IV congestive heart failure * LVEF ≥ 45% by 2-D ECHO or MUGA * No acute ischemia or new conduction system abnormality by EKG * No conduction system abnormality (e.g., left bundle branch block) by EKG that would preclude the ability to detect new ischemic episodes * No myocardial infarction within the past 6 months * No significant comorbidity, such as poorly controlled hypertension, diabetes mellitus, or other serious medical or psychiatric illness that, in the opinion of the investigator, might compromise any aspect of the study * No uncontrolled infection * Patients may have febrile episodes up to 38.5°C if these are felt to be due to tumor fever and the possibility of infection has been ruled out by evaluation * No prior hypersensitivity reaction to pegylated doxorubicin hydrochloride liposome or doxorubicin hydrochloride * Patients with a history of reactions to other liposomal drug formulations and/or to the liposome itself, as opposed to the encapsulated agent, may be excluded at the discretion of the investigator Phase II * Female or male * Menopausal status not specified * Karnofsky performance status 70-100% * Life expectancy ≥ 3 months * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception during and for 3 months after completion of study therapy * ANC ≥ 1,500/mm³ * Platelet count ≥ 100,000/mm³ * Hemoglobin ≥ 9.0 g/dL * Creatinine ≤ 2.5 mg/dL (≤ 200 µmol/L) * AST and ALT ≤ 2 times ULN * Alkaline phosphatase ≤ 2 times ULN (unless attributed to tumor) * Bilirubin ≤ ULN * Cardiac ejection fraction \> 50% by MUGA or 2-D ECHO * No clinical evidence of congestive heart failure * No New York Heart Association class II-IV cardiac disease * No myocardial infarction within the past 6 months * No uncontrolled angina * No severe uncontrolled ventricular arrhythmias * No evidence of acute ischemia or active conduction system abnormalities by EKG * Any EKG abnormality at screening must be documented by the investigator as not medically relevant * No grade 2 peripheral neuropathy within the past 14 days * No significant comorbidity that would impair compliance with study therapy or interpretation of study results * No history of hypersensitivity reactions attributed to a conventional formulation of doxorubicin hydrochloride or the components of pegylated doxorubicin hydrochloride liposome * No hypersensitivity to bortezomib, boron, or mannitol * No serious medical or psychiatric illness likely to interfere with participation in this study PRIOR CONCURRENT THERAPY: Phase I (closed to accrual as of 10/15/2007) * More than 3 weeks since prior major surgery * More than 3 weeks since prior and no concurrent radiotherapy * More than 4 weeks since prior and no concurrent immunotherapy (i.e., interferon, interleukin, or other cytokine-based treatment) * More than 3 weeks since prior and no concurrent participation in another therapeutic clinical trial with an experimental drug * More than 3 weeks since prior and no other concurrent chemotherapy * No prior doxorubicin dose \> 400 mg/m² * No other concurrent antineoplastic therapy Phase II * More than 6 months since prior anthracyclines * More than 14 days since other prior investigational drugs * No more than 300 mg/m² of prior doxorubicin or 540 mg/m² of prior epirubicin * No more than two prior chemotherapy regimens for metastatic disease * No other concurrent antineoplastic therapy